Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Carfilzomib clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Carfilzomib as a study intervention. Browse Carfilzomib recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 9:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
193
Shown on this page
12
Current sort
Recently updated
Therapy scope
Carfilzomib
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Carfilzomib. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 157–168 of 193 matching trials for Carfilzomib.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Completed Phase 2 Interventional Results available

Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment

NCT02047253
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Carfilzomib, Dexamethasone, Acyclovir
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Birmingham, Alabama • Macon, Georgia • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 19, 2026, 9:30 AM EDT
Completed Phase 2 Interventional Results available

Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia

NCT01470196
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia
Interventions
Dexamethasone, Carfilzomib, Rituximab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Oct 19, 2026, 9:30 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation

NCT01690143
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Carfilzomib, Melphalan
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
4
States / cities
Birmingham, Alabama • New York, New York • Charleston, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 19, 2026, 9:30 AM EDT
Completed Phase 2 Interventional Results available

A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols

NCT00884312
View directory record Official record
Conditions
Multiple Myeloma, Solid Tumors
Interventions
Carfilzomib
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
21
States / cities
Scottsdale, Arizona • Beverly Hills, California • Duarte, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Oct 19, 2026, 9:30 AM EDT
Completed Phase 1Phase 2 Interventional

Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments

NCT01365559
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Group A: Carfilzomib & Non-IMiD Regimen, Group B: Carfilzomib & IMiD containing regimen.
Drug
Lead sponsor
Oncotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
9
States / cities
Encinitas, California • Salinas, California • Santa Maria, California + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2018 · Synced Oct 19, 2026, 9:30 AM EDT
Not listed Phase 1Phase 2 Interventional

Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma

NCT01792102
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Carfilzomib and Dexamethasone
Drug
Lead sponsor
Oncotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
West Hollywood, California • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 5, 2018 · Synced Oct 19, 2026, 9:30 AM EDT
Completed Phase 1 Interventional

Carfilzomib Plus Belinostat in Relapsed/Refractory NHL

NCT02142530
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Peripheral T-cell Lymphoma
Interventions
Carfilzomib, Belinostat
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 25, 2018 · Synced Oct 19, 2026, 9:30 AM EDT
Completed Phase 1 Interventional Results available

Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma

NCT00963820
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Ixazomib citrate
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
6
States / cities
Scottsdale, Arizona • West Hollywood, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced Oct 19, 2026, 9:30 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma

NCT01057225
View directory record Official record
Conditions
Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
carfilzomib, cyclophosphamide, thalidomide, dexamethasone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
3
States / cities
Scottsdale, Arizona • Rochester, Minnesota • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 19, 2026, 9:30 AM EDT
Terminated Phase 2 Interventional Results available

Study of Carfilzomib in Combination w/Dexamethasone in Patients w/Newly Diagnosed Multiple Myeloma

NCT01969565
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Carfilzomib, Dexamethasone
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Oct 19, 2026, 9:30 AM EDT
Completed Phase 1 Interventional

A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis

NCT01789242
View directory record Official record
Conditions
Amyloidosis, Systemic Light Chain Amyloidosis
Interventions
Carfilzomib, Dexamethasone
Drug
Lead sponsor
Criterium, Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
10
States / cities
Duarte, California • Stanford, California • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2017 · Synced Oct 19, 2026, 9:30 AM EDT
Completed Phase 1 Interventional

A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma

NCT01660750
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Carfilzomib, Cyclophosphamide, Dexamethasone
Drug
Lead sponsor
Criterium, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
5
States / cities
Los Angeles, California • Palm Springs, California • Worcester, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2017 · Synced Oct 19, 2026, 9:30 AM EDT

About this Carfilzomib clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Carfilzomib as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Carfilzomib.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Carfilzomib.